Australian Critical Care
Volume 20, Issue 1 , Pages 15-26 , February 2007

Anticoagulation in CRRT: Agents and strategies in Australian ICUs

  • Hugh Davies, RN, B. Nurs., Post Grad Dip. (Intensive Care), MHM, ACCN

      Affiliations

    • Intensive Care Unit, Royal Perth Hospital, Western Australia, Australia
    • Corresponding Author InformationCorresponding author at: Intensive Care Unit, Royal Perth Hospital, Wellington Street, Perth, Western Australia 6000, Australia. Tel.: +61 8 9224 2244.
    • ,
  • Gavin Leslie, RN, PhD, B App. Sc., Post Grad Dip. (Clinical Nursing), FRCNA

      Affiliations

    • Critical Care Nursing, Royal Perth Hospital and Edith Cowan University, Western Australia, Australia

References 

  1. Holt AW, Bierer P, Glover P, Plummer JL, Bersten AD. Conventional coagulation and thromboelastograph parameters and longevity of continuous renal replacement circuits. Intensive Care Med. 2002;28:1649–1655
  2. Stefanidis I, Hagel J, Frank D, Maurin N. Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure. Clin Nephrol. 1996;46(3):199–205
  3. Kox WJ, Rohr U, Waurer H. Practical aspects of renal replacement therapy. Int J Artif Organs. 1996;19:100–105
  4. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous haemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000;26:1652–1657
  5. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis. 1997;30(5 Suppl. 4):S20–S27
  6. Bellomo R, Ronco C. Anticoagulation during CRRT. In:  Bellomo R,  Baldwin I,  Ronco C,  Golper T editor. Atlas of haemofiltration. Sydney: W.B. Saunders; 2002;p. 63–68
  7. Mehta RL. Anticoagulation strategies for continuous renal replacement therapies: what works?. Am J Kidney Dis. 1996;28(5 Suppl. 3):S8–S14
  8. Oudemans-van Straaten HM, Wester JPJ, de Pont ACJM, Schetz M. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?. Intensive Care Med. 2006;32:188–202
  9. Silvester W, Bellomo R, Cole L. Epidemiology, management and outcome of severe acute renal failure of critical illness in Australia. Crit Care Med. 2001;29:1910–1915
  10. Wright SE, Bodenham A, Short AIK, Turney JH. The provision and practice of renal replacement therapy on adult intensive care units in the United Kingdom. Anaesthesia. 2003;58:1063–1069
  11. Shulman RI, Singer M, Rock J. Keeping the circuit open: lessons from the lab. Blood Purificat. 2002;20:275–281
  12. Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL. Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Med. 1994;20:212–215
  13. Abramson S, Niles JL. Anticoagulation in continuous renal replacement therapy. Curr Opin Nephrol Hypertens. 1999;8:701–707
  14. Schetz M. Anticoagulation for continuous renal replacement therapy. Curr Opin Anaesthesiol. 2001;14:143–149
  15. Webb AR, Mythen MG, Jacobson D, Mackie IJ. Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Intensive Care Med. 1995;21:84–93
  16. Hillman RS, Ault KA. Clinical approach to bleeding disorders. Hematology in clinical practice. 3rd ed.. New York: McGraw-Hill; 2002;p. 308–15
  17. Davenport A. Anticoagulation for continuous renal replacement therapy. Contribut Nephrol. 2004;144:228–238
  18. Opatrny KJ, Polanska K, Krouzecky A, Vit L, Novak I, Kasal E. The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration. Int J Artif Organs. 2002;25(6):520–528
  19. Leslie GD, Jacobs IG, Clarke GM. Proximally delivered dilute heparin does not improve circuit life in continuous veno-venous haemodiafiltration. Intensive Care Med. 1996;22:1261–1264
  20. van de Wetering J, Westendrop RGJ, van der Hoeven JG, Stolk B, Feuth JDM, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient haemorrhage. J Am Soc Nephol. 1996;7(1):145–150
  21. Baldwin I, Tan HK, Bridge N, Bellomo R. A prospective study of thromboelastography (TEG) and filter life during continuous veneo-venous hemofiltration. Ren Fail. 2000;22(3):297–306
  22. Kaplan AA, Longnecker RE, Folkert VW. Continuous arteriovenous hemofiltration: a report of six month's experience. Ann Intern Med. 1984;100:358–367
  23. Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int. 1993;43(Suppl. 41):S237–S244
  24. Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis. 1994;24:806–812
  25. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1:1471–1478
  26. Davenport A. Heparin-induced thrombocytopenia during renal replacement therapy. Hemodialysis Int. 2004;8:295–303
  27. Mehta RL, Dobos GJ, Ward DM. Anticoagulation in continuous renal replacement procedures. Semin Dial. 1992;5(1):61–68
  28. Kaplan AA, Petrillo R. Regional heparinization for continuous arterio-venous hemofiltration (CAVH). Trans Am Soc Artif Organs. 1987;33:312–315
  29. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol. 2003;16:566–571
  30. Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration. Intensive Care Med. 1993;19:329–332
  31. Horrow JC. Protamine: a review of its toxicity. Anesth Analg. 1985;64:348–361
  32. Carr JA, Silverman N. The heparin-protamine interaction: a review. J Cardiovasc Surg. 1999;40(5):659–666
  33. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330–1335
  34. Jeffrey RF, Khan AA, Douglas JT, Will EJ, Davison AM. Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. Artif Organs. 1993;17:717–720
  35. de Pont ACJM, Oudemans-vanStraaten HM, Roozendaal KJ, Zandstra DF. Nadroparin versus dalteparin anticoagulation in high-volume continuous venovenous hemofiltration: a double blind, randomized, crossover study. Crit Care Med. 2000;28:421–425
  36. Reeves JH, Cumming AR, Gallagher L, O’Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med. 1999;27(10):2224–2228
  37. Joannidis M, Kountchew J, Grote A, Bellmann R, Mayr A, Wiedermann C. Unfractionated versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH (abstract). Intensive Care Med. 2004;30:S155
  38. Vun CM, Evans S, Chong BH. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res. 1996;81(5):525–532
  39. Wester JPJ. Guidelines for anticoagulation with danaparoid sodium and lepirudin in continuous venovenous hemofiltration. Neth J Crit Care. 2004;8(4):293–301
  40. Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparinoid (Danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb/Hemost. 2001;7(4):300–304
  41. Davenport A. Anticoagulation in patients with acute renal failure treated with continuous renal replacement therapies. Hemodialysis Int. 1998;2:41–59
  42. Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: Single-center experience. Nephron Clin Pract. 2004;97:c131–c136
  43. Cointault O, Kamar N, Bories P, Lavayssiere L, Angles O, Rostaing L, et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant. 2004;19:171–178
  44. Hofmann RM, Maloney C, Ward DM, Becker BN. A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF). Ren Fail. 2002;24(3):325–335
  45. Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous veno-venous hemodiafiltration. Am J Kidney Dis. 2000;35(5):802–811
  46. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67:2361–2367
  47. Mehta RL, Mc Donald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976–981
  48. Mitchell A, Daul AE, Beiderlinden M, Schafers RF, Heemann U, Kribben A, et al. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clin Nephrol. 2003;59(2):106–114
  49. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260–265
  50. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999;55:1991–1997
  51. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int. 2001;60:370–374
  52. Bagshaw SM, Laupland KB, Boiteau PJE, Godinez-Luna T. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care. 2005;20(2):155–161
  53. Naka T, Egi M, Bellomo R, Cole L, French C, Botha J, et al. Commercial low-citrate anticoagulation haemofiltration in high risk patients with frequent filter clotting. Anaesth Intensive Care. 2005;33(5):601–608
  54. Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol. 2006;1(1):79–87
  55. Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005;20(7):1416–1421
  56. Scheeren T, Radermacher P. Prostacyclin (PG12): new aspects of an old substance in the treatment of criticall ill patients. Intensive Care Med. 1997;23:146–158
  57. Ponikvar R, Kandus A, Buturovic J, Kveder R. Use of prostacyclin as the only anticoagulant during continuous venovenous hemofiltration. Contribut Nephrol. 1991;93:218–220
  58. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron. 1994;66:431–437
  59. Fiaccadori E, Maggiore U, Rotelli C, Minari M, Melfa L, Cappe G, et al. Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med. 2002;28:586–593
  60. Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med. 1994;22(11):1774–1781
  61. Canaud B, Mion C, Arujo A, N’ Guyen VQ, Paleyrac G, Hemmendinger S, et al. Prostacyclin (Epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration. Nephron. 1988;48:206–212
  62. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73–80
  63. Fischer KG, van de Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int. 1999;56(Suppl. 72):S46–S50
  64. Kern H, Ziemer S, Kox WJ. Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med. 1999;25:1311–1314
  65. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, Berends F, Hommes DW, Rijnierse JJMM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment. Thromb Haemost. 1994;72(5):685–692
  66. Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of the whole blood ecarin clotting time. Thromb Haemost. 1997;77(5):920–925
  67. Hein OV, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer H, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med. 2001;27:673–679
  68. Hein OV, von Heymann C, Diehl T, Ziemer S, Ronco C, Morgera S, et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Ren Fail. 2004;26(3):297–303
  69. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost. 1996;22(2):197–202
  70. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost. 2002;28(5):467–482
  71. Frank D, Farber H, Lanzmich R, Floege J, Kierdorf H. In vitro studies on hirudin elimination by haemofiltration: comparison of three high-flux membranes. Nephrol Dial Transplant. 2002;17:1957–1963
  72. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinent human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709
  73. Abbenbroek B, Baldwin I, Boyle M, Foster M, Hunt T, Leslie GD, et al. Nursing Guidelines for the use of Xigris (drotrecogin alfa [activated] rhu). Printed by Lilly, 2004.
  74. de Pont ACJM, Bouman CSC, Jonge Ed , Vroom MB, Buller HR, Levi M. Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous veneovenous hemofiltration in patients with severe sepsis. Intensive Care Med. 2003;29(7):1205
  75. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous venovenous hemofiltration without anticoagulation. Am Soc Artif Intern Organs J. 2004;50:76–80
  76. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Pre-dilution versus Post-dilution during continuous veno-venous hemofiltration: impact on filter and azotemic control. Nephron Clin Practice. 2003;94:c94–c98

PII: S1036-7314(06)00003-8

doi: 10.1016/j.aucc.2006.11.001

Australian Critical Care
Volume 20, Issue 1 , Pages 15-26 , February 2007

Article Tools

* Image Usage & Resolution